The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy

Current Diabetes Reports

Volumn 14, Issue 10, 2014, Pages

  Lauria, Giuseppe ^a   Ziegler, Dan ^b,c   Malik, Rayaz ^d,e   Merkies, Ingemar S J ^f,i   Waxman, Stephen G ^g,h   Faber, Catharina G ⁱ  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f Department of Orthopaedic Surgery   (Netherlands)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetic neuropathy; Idiopathic neuropathy; Neuropathic pain; Neurophysiology; Nociception; Painful neuropathy; Skin biopsy; Sodium channels

Indexed keywords

SODIUM CHANNEL; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.6; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.9; ANALGESIC AGENT; SODIUM CHANNEL BLOCKING AGENT;

ANALGESIA; DIABETIC NEUROPATHY; FLUSHING; GAIN OF FUNCTION MUTATION; HUMAN; IDIOPATHIC NEUROPATHY; LOSS OF FUNCTION MUTATION; METABOLIC REGULATION; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; REVIEW; DIABETIC NEUROPATHIES; DRUG EFFECTS; METABOLISM; PAIN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

ANALGESICS; DIABETIC NEUROPATHIES; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TREATMENT OUTCOME;

EID: 84919443732     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0538-5     Document Type: Review

References (91)

1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
2. Lauria G, Faber CG, Merkies IS, Waxman SG. Diagnosis of neuropathic pain: challenges and possibilities. Expert Opin Med Diagn. 2012;6(2):89–93. doi:10.1517/17530059.2012.661712.
3. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain. 2008;138(2):343–53.
4. Sommer C, Richter H, Rogausch JP, Frettloh J, Lungenhausen M, Maier C. A modified score to identify and discriminate neuropathic pain: a study on the German version of the neuropathic pain symptom inventory (NPSI). BMC Neurol. 2011;11:104.
5. Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150(3):439–50.
6. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(Pt 7):1912–25. doi:10.1093/brain/awn093.
7. Nolano M, Crisci C, Santoro L, Barbieri F, Casale R, Kennedy WR, et al. Absent innervation of skin and sweat glands in congenital insensitivity to pain with anhidrosis. Clin Neurophysiol. 2000;111(9):1596–601.
8. Nolano M, Provitera V, Crisci C, Saltalamacchia AM, Wendelschafer-Crabb G, Kennedy WR, et al. Small fibers involvement in Friedreich’s ataxia. Ann Neurol. 2001;50(1):17–25.
9. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8(7):654–67. doi:10.1016/S1474-4422(09)70110-3.
10. England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151–61. doi:10.1016/S0140-6736(04)16508-2.
11. Said G. Diabetic neuropathy—a review. Nat Clin Pract Neurol. 2007;3(6):331–40.
12. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378(9786):169–81. doi:10.1016/S0140-6736(11)60614-4. An updated overview on type 2 diabetes and its complications.
13. Sabin TD, Geschwind N, Waxman SG. Patterns of clinical deficits in peripheral nerve disease. In: Waxman SG, editor. Physiology and pathobiology of axons. New York: Raven; 1978. p. 431–9.
14. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–4. The most recent and largest epidemiological survey on diabetic neuropathy.
15. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9(6):660–74.
16. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67(4):534–41.
17. Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies—advances in diagnosis, pathophysiology and management. Nat Rev Neurol. 2012;8(7):369–79. doi:10.1038/nrneurol.2012.97.
18. Lauria G, Merkies IS, Faber CG. Small fibre neuropathy. Curr Opin Neurol. 2012;25(5):542–9.
19. Hughes RA, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127(Pt 8):1723–30.
20. Young EE, Lariviere WR, Belfer I. Genetic basis of pain variability: recent advances. J Med Genet. 2012;49(1):1–9. A review on the variability of pain features in human diseases and genes.
21. Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat Commun. 2012;3:1186. doi:10.1038/ncomms2184. Description of a combined atomic-level modelling/thermodynamic approach to pain-related sodium channel mutations for prediction of response to analgesics.
22. Waxman SG. The neuron as a dynamic electrogenic machine: modulation of sodium-channel expression as a basis for functional plasticity in neurons. Philos Trans R Soc Lond B Biol Sci. 2000;355(1394):199–213. doi:10.1098/rstb.2000.0559.
23. Black JA, Foster RE, Waxman SG. Freeze-fracture ultrastructure of rat C.N.S. and P.N.S. nonmyelinated axolemma. J Neurocytol. 1981;10(6):981–93.
24. Feinberg K, Eshed-Eisenbach Y, Frechter S, Amor V, Salomon D, Sabanay H, et al. A glial signal consisting of gliomedin and NrCAM clusters axonal Na+ channels during the formation of nodes of Ranvier. Neuron. 2010;65(4):490–502. doi:10.1016/j.neuron.2010.02.004.
25. Waxman SG, Foster RE. Development of the axon membrane during differentiation of myelinated fibres in spinal nerve roots. Proc R Soc Lond B Biol Sci. 1980;209(1176):441–6.
26. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57(4):411–25.
27. Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci. 2014;17(2):153–63. doi:10.1038/nn.3602. A review on key ion channels in the pain pathway, their role in human pain diseases and the candidate targets for novel analgesics.
28. Black JA, Frezel N, Dib-Hajj SD, Waxman SG. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. Mol Pain. 2012;8:82. Describes the distribution of the Nav1.7 sodium channel subunit throughout the nociceptive pathway from the skin endings to the dorsal horn.
29. Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998;18(23):9607–19.
30. Minett MS, Nassar MA, Clark AK, Passmore G, Dickenson AH, Wang F, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3:791. Suggests a role of Nav1.7 in the transmission of pain signals to second-order neurons within the dorsal horn.
31. Waxman SG. Neurobiology: a channel sets the gain on pain. Nature. 2006;444(7121):831–2. doi:10.1038/444831a.
32. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257–62. doi:10.1038/379257a0.
33. Choi JS, Waxman SG. Physiological interactions between Na(v)1.7 and Na(v)1.8 sodium channels: a computer simulation study. J Neurophysiol. 2011;106(6):3173–84. Provides data on the relative effects of Nav1.7 and Nav1.8 expression on DRG excitability and firing properties.
34. Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol. 2001;86(2):629–40.
35. Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW, Kobayashi J, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007;447(7146):855–8.
36. Abrahamsen B, Zhao J, Asante CO, Cendan CM, Marsh S, Martinez-Barbera JP, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science (New York, NY). 2008;321(5889):702–5. doi:10.1126/science.1156916.
37. Vetter I, Touska F, Hess A, Hinsbey R, Sattler S, Lampert A, et al. Ciguatoxins activate specific cold pain pathways to elicit burning pain from cooling. EMBO J. 2012;31(19):3795–808. doi:10.1038/emboj.2012.207. Suggests a molecular basis for an acquired painful disease specifically causing cold allodynia.
38. Deuis JR, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154(9):1749–57. doi:10.1016/j.pain.2013.05.032. Suggests a molecular basis to explain the specific occurrence of cold allodynia in oxaliplatin-related neuropathy.
39. Rugiero F, Mistry M, Sage D, Black JA, Waxman SG, Crest M, et al. Selective expression of a persistent tetrodotoxin-resistant Na+ current and NaV1.9 subunit in myenteric sensory neurons. J Neurosci. 2003;23(7):2715–25.
40. Black JA, Waxman SG. Molecular identities of two tetrodotoxin-resistant sodium channels in corneal axons. Exp Eye Res. 2002;75(2):193–9.
41. Dib-Hajj S, Black JA, Cummins TR, Waxman SG. NaN/Nav1.9: a sodium channel with unique properties. Trends Neurosci. 2002;25(5):253–9.
42. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J Neurosci. 1999;19(24):RC43.
43. Herzog RI, Cummins TR, Waxman SG. Persistent TTX-resistant Na+ current affects resting potential and response to depolarization in simulated spinal sensory neurons. J Neurophysiol. 2001;86(3):1351–64.
44. Copel C, Osorio N, Crest M, Gola M, Delmas P, Clerc N. Activation of neurokinin 3 receptor increases Na(v)1.9 current in enteric neurons. J Physiol. 2009;587(Pt 7):1461–79.
45. Baker MD, Chandra SY, Ding Y, Waxman SG, Wood JN. GTP-induced tetrodotoxin-resistant Na+ current regulates excitability in mouse and rat small diameter sensory neurones. J Physiol. 2003;548(Pt 2):373–82. doi:10.1113/jphysiol.2003.039131.
46. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007;117(12):3603–9. doi:10.1172/JCI33297.
47. Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol. 2005;124(6):1333–8. doi:10.1111/j.0022-202X.2005.23737.x.
48. Hayden R, Grossman M. Rectal, ocular, and submaxillary pain; a familial autonomic disorder related to proctalgia fugaz: report of a family. AMA J Dis Child. 1959;97(4):479–82.
49. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–74. doi:10.1016/j.neuron.2006.10.006.
50. Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012;153(1):80–5. doi:10.1016/j.pain.2011.09.008.
51. Umapathi T, Tan WL, Loke SC, Soon PC, Tavintharan S, Chan YH. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve. 2007;35(5):591–8.
52. Loseth S, Stalberg E, Jorde R, Mellgren SI. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol. 2008;255(8):1197–202.
53. Lauria G, Morbin M, Lombardi R, Borgna M, Mazzoleni G, Sghirlanzoni A, et al. Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology. 2003;61(5):631–6.
54. Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili G, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst. 2010;15(3):202–7.
55. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. J Periph Nerv Syst. 2010;15(2):79–92.
56. Lauria G. Innervation of the human epidermis. A historical review. Ital J Neurol Sci. 1999;20(1):63–70.
57. Stogbauer F, Young P, Kuhlenbaumer G, Kiefer R, Timmerman V, Ringelstein EB, et al. Autosomal dominant burning feet syndrome. J Neurol Neurosurg Psychiatry. 1999;67(1):78–81.
58. Kuhlenbaumer G, Young P, Kiefer R, Timmerman V, Wang JF, Schroeder JM, et al. A second family with autosomal dominant burning feet syndrome. Ann N Y Acad Sci. 1999;883:445–8.
59. Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, et al. Gain of function Na(V) 1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 2012;71(1):26–39. First demonstration that mutations of SCN9A gene encoding for Nav1.7 can cause painful small fiber neuropathy.
60. Han C, Hoeijmakers JG, Ahn HS, Zhao P, Shah P, Lauria G, et al. Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology. 2012;78(21):1635–43. Provides mechanistic insights into the change of nociceptor excitability and sodium channel currents underlying painful symptoms.
61. Faber CG, Lauria G, Merkies IS, Cheng X, Han C, Ahn HS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A. 2012;109(47):19444–9. First demonstration of involvement of Nav1.8 mutations in diabetic painful neuropathy.
62. Huang J, Yang Y, Zhao P, Gerrits MM, Hoeijmakers JG, Bekelaar K, et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci. 2013;33(35):14087–97.
63. Han C, Vasylyev D, Macala LJ, Gerrits MM, Hoeijmakers JG, Bekelaar KJ, et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry. 2014;85(5):499–505. doi:10.1136/jnnp-2013-306095.
64. Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG, Gerrits MM, et al. Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy. Brain. 2014. doi:10.1093/brain/awu079. Demonstrated that the spectrum of sodium channel-related painful small fiber neuropathy extends to novel mutations in the SCN11A gene encoding Nav1.9.
65. Hoeijmakers JG, Han C, Merkies IS, Macala LJ, Lauria G, Gerrits MM, et al. Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation. Brain. 2012;135(Pt 2):345–58. doi:10.1093/brain/awr349. Description of kindred with a novel genetic syndrome associated with a Nav1.7 mutation.
66. Estacion M, Han C, Choi JS, Hoeijmakers JG, Lauria G, Drenth JP, et al. Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain. 2011;7:92.
67. Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH, Lauria G, et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain. 2012;135(Pt 9):2613–28. doi:10.1093/brain/aws187. Demonstrated the differing effects of single mutations of Nav1.7 on nociceptors and sympathetic neurons, explaining the occurrence of pain and dysautonomia in patients.
68. Devigili G, Eleopra R, Pierro T, Lombardi R, S. R, Lettieri C, et al. Paroxysmal itch caused by gain-of-function Nav1.7 mutation. Pain. 2014
69. Anesthesiologists ASo. Practice guidelines for chronic pain management. Anesthesiology. 2010;112:810–33.
70. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88.
71. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol. 2002;52(6):786–92. doi:10.1002/ana.10364.
72. Hong S, Morrow TJ, Paulson PE, Isom LL, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem. 2004;279(28):29341–50. doi:10.1074/jbc.M404167200.
73. Shah BS, Gonzalez MI, Bramwell S, Pinnock RD, Lee K, Dixon AK. Beta3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci Lett. 2001;309(1):1–4.
74. Hirade M, Yasuda H, Omatsu-Kanbe M, Kikkawa R, Kitasato H. Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience. 1999;90(3):933–9.
75. Krishnan AV, Lin CS, Kiernan MC. Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain. 2008;131(Pt 5):1209–16. doi:10.1093/brain/awn052.
76. Zenker J, Poirot O, de Preux Charles AS, Arnaud E, Medard JJ, Lacroix C, et al. Altered distribution of juxtaparanodal kv1.2 subunits mediates peripheral nerve hyperexcitability in type 2 diabetes mellitus. J Neurosci. 2012;32(22):7493–8.
77. Misawa S, Sakurai K, Shibuya K, Isose S, Kanai K, Ogino J, et al. Neuropathic pain is associated with increased nodal persistent Na(+) currents in human diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):279–84. doi:10.1111/j.1529-8027.2009.00239.x.
78. Quasthoff S. The role of axonal ion conductances in diabetic neuropathy: a review. Muscle Nerve. 1998;21(10):1246–55.
79. Sun W, Miao B, Wang XC, Duan JH, Wang WT, Kuang F, et al. Reduced conduction failure of the main axon of polymodal nociceptive C-fibres contributes to painful diabetic neuropathy in rats. Brain. 2012;135(Pt 2):359–75. doi:10.1093/brain/awr345. Provides compelling evidence on the pathogenetic effect of hyperglycemia on physiological properties of unmyelinated axons, implicating Nav1.8.
80. Zhu ZR, Tang XW, Wang WT, Ren W, Xing JL, Zhang JR, et al. Conduction failures in rabbit saphenous nerve unmyelinated fibers. Neuro-Signals. 2009;17(3):181–95. doi:10.1159/000209279.
81. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, et al. Methylglyoxal modification of Na(v)1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature medicine. 2012. Explains a new metabolically driven molecular mechanism underlying neuropathic pain in experimental diabetic neuropathy.
82. Thornalley PJ. Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci. 2005;1043:111–7. doi:10.1196/annals.1333.014.
83. Fleming T, Nawroth PP. Reactive metabolites as a cause of late diabetic complications. Biochem Soc Trans. 2014;42(2):439–42. doi:10.1042/BST20130265.
84. Jack MM, Ryals JM, Wright DE. Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy. Diabetologia. 2011;54(8):2174–82. doi:10.1007/s00125-011-2196-3.
85. Andersson DA, Gentry C, Light E, Vastani N, Vallortigara J, Bierhaus A, et al. Methylglyoxal evokes pain by stimulating TRPA1. PLoS One. 2013;8(10):e77986. doi:10.1371/journal.pone.0077986.
86. Zuliani V, Rivara M, Fantini M, Costantino G. Sodium channel blockers for neuropathic pain. Expert Opin Ther Patents. 2010;20(6):755–79. doi:10.1517/13543771003774118.
87. Zhang JL, Yang JP, Zhang JR, Li RQ, Wang J, Jan JJ, et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res. 2013;1493:13–8.
88. Tanaka KI, Nakanishi Y, Sekino S, Ikegami M, Ikeda H, Kamei J. Fentanyl produces an anti-hyperalgesic effect through the suppression of sodium channels in mice with painful diabetic neuropathy. Eur J Pharmacol. 2014;733C:68–74. doi:10.1016/j.ejphar.2014.03.042.
89. Chattopadhyay M, Mata M, Fink DJ. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci. 2008;28(26):6652–8.
90. Chattopadhyay M, Mata M, Fink DJ. Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur J Pain (Lond Engl). 2011;15(9):913–20. doi:10.1016/j.ejpain.2011.03.007.
91. Mert T, Gunes Y. Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats. J Am Assoc Lab Anim Sci. 2012;51(5):579–85.